Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities
Healthcare - Press Releases
- 1045 Press Releases ยท
- RSS
Published on Mon 10 Mar 2025 8:18:46 UTC
SAN DIEGO, March 10, 2025 /PRNewswire/ -- A new study presented at the 2025 Annual Meeting of the American Academy of Orthopaedic Surgeons(AAOS) examined the impact of a policy implemented by the United States Soccer Federation (USSF) to address youth players heading the soccer ball. Researchers found that the policy was associated with a decrease in soccer-related concussions; however, female players experienced a higher proportion of concussions than their male counterparts.
Published on Mon 10 Mar 2025 5:07:49 UTC
USA News Group News Commentary
Published on Mon 10 Mar 2025 5:07:46 UTC
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm
Published on Mon 10 Mar 2025 5:07:44 UTC
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) --
Published on Mon 10 Mar 2025 5:07:39 UTC
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg
Published on Mon 10 Mar 2025 5:07:34 UTC
ELKO, Nev., 8 de marzo de 2025 /PRNewswire-HISPANIC PR WIRE/ -- Community Health Development Partners (CHDP), en colaboracin con Nevada Gold Mines (NGM), operado por Barrick, se complace en anunciar la gran apertura del Centro de Infusin CHDP en Elko, Nevada. Esta instalacin de vanguardia ahora est abierta para atender a pacientes que requieren tratamiento contra el cncer, as como infusiones e inyecciones no relacionadas con el cncer.
Published on Mon 10 Mar 2025 5:07:33 UTC
BARCELONA, Spanien, 8. Mrz 2025 /PRNewswire/ -- Whrend des Mobile World Congress (MWC) 2025 hielt Huawei einen Vortrag zur globalen Gesundheitsbranche mit dem Thema Digitale Intelligenz frdert eine inklusive Gesundheitsversorgung ab. Expertenteilten ihre neuesten Strategien und Praktiken fr die digitale Transformation und die Entwicklung von KI-Anwendungen.
Published on Mon 10 Mar 2025 5:07:29 UTC
BARCELONA, Spanje, 8 maart 2025 /PRNewswire/ -- Tijdens het Mobile World Congress (MWC) 2025 hield Huawei een sessie over de mondiale gezondheidszorg met als thema Digital Intelligence Drives Inclusive Healthcare. Expertsdeelden hun nieuwste strategien en praktijken op gebied van digitale transformatie en de ontwikkeling van AI-toepassingen.
Published on Mon 10 Mar 2025 5:07:24 UTC
CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trialto primarily enroll women using the two most widely used global TAVR devices
Published on Mon 10 Mar 2025 5:07:23 UTC
Conference call and webcast to be held at 8:30 a.m. ET
Published on Mon 10 Mar 2025 5:07:19 UTC
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announcedthe U.S. Food and Drug Administration (FDA) approved OMLYCLO (omalizumab-igec)as the first and only biosimilar designated as interchangeable with XOLAIR (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2]
Published on Mon 10 Mar 2025 5:07:15 UTC
PRINCETON, N.J., March 9, 2025 /PRNewswire/ --RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, todayannouncedthat the first patient was dosedlast week in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation.
Published on Mon 10 Mar 2025 5:07:11 UTC
(PRNewsfoto/Sun Pharmaceutical Industries Inc., USA (Sun Pharma))
Published on Mon 10 Mar 2025 5:07:08 UTC
HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), Glucagon-like peptide-1 receptor (GLP-1R) has completed the enrollment in the Phase 2 clinical study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG) ("DR10624-201 study").
Published on Mon 10 Mar 2025 5:07:00 UTC
PRINCETON, N.J., March 10, 2025 /PRNewswire/ -- Kenox Pharmaceuticals Inc. and Lactiga US, Inc. are pleased to announce a strategic collaboration to advance the development of novel, groundbreaking, mucosal-targeted Secretory IgA (sIgA) therapies for immunodeficient patients. This partnership is supported by a significant multi-million-dollar STTR grant awarded to Lactiga by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Published on Mon 10 Mar 2025 5:04:23 UTC
Leadership transition comes as Company focuses on clinical evaluation of its novel OvarianRebalancing technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility
Published on Mon 10 Mar 2025 5:04:20 UTC
Leadership transition comes as Company focuses on clinical evaluation of its novel OvarianRebalancing technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility
Published on Mon 10 Mar 2025 4:59:13 UTC
LAS VEGAS, March 9, 2025 /PRNewswire/ --C-suite leaders fromHouston Methodist and Health Data Analytics Institute (HDAI) will be speaking at HumanX, discussing how AI can play a pivotal role in addressing the looming hospital capacity crisisand out of control healthcare expenses, while also improving quality and reducing epidemic levels of clinician burnout.
Published on Mon 10 Mar 2025 4:58:54 UTC
BOSTON, March 9, 2025 /PRNewswire/ -- OnPoint AR-AI, a group of privately held augmented reality (AR) technology companies pioneering AR guidance and machine learning for neurosurgical and orthopedic spinal procedures, including robotic procedures, today announced that it will participate in the 2025 Canaccord Genuity Musculoskeletal Conference on Monday, March 10, 2025, at the Westin San Diego Gaslamp. Philipp Lang, MD, Chairman and CEO, and Grace Connelly, CFO, will represent the Company in a presentation scheduled for 11.30 a.m. Pacific Time.
Published on Mon 10 Mar 2025 4:58:52 UTC
HONG KONG, March 9, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5GUAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology and Zhejiang University was awarded the Global Mobile Award (GLOMO Award) for "Best Mobile Innovation for Connected Health and Wellbeing." This groundbreaking achievement signifies that the integration of "5G + low-altitude + healthcare" is poised to enter the stage of large-scale application, opening up new pathways for the equitable distribution of medical resources worldwide.
Published on Mon 10 Mar 2025 4:58:46 UTC
Improving outcomes for aging and high-need populations
Published on Fri 7 Mar 2025 10:10:18 UTC
The makers of ZYMOX welcome Michael Watkins, Paul Mattas and Paul Zahn
Published on Fri 7 Mar 2025 10:10:13 UTC
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pembrolizumab monotherapy in the first-line treatment of PD-L1 positive (PD-L1 TPS 1%) locally advanced or metastatic non-small cell lung cancer (NSCLC) have been published in The Lancet.
Published on Fri 7 Mar 2025 10:10:09 UTC
Innovative products like wipes, washes, and lotions comprised of skin- and eco-friendly substances are likely to be introduced to the market. Product customization according to particular skin types or needs is also anticipated to rise.
Published on Fri 7 Mar 2025 10:10:05 UTC
Strategic partnership with Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd ("SPH Kyuan Trade") to transform access to Wilson's diseasetreatment for Chinese patients
Press Release by Industry
- All Industries
- Agriculture
- Automotive
- Banking
- Business Technology
- Construction
- Consumer Goods
- Consumer Technology
- Education
- Energy
- Entertainment & Media
- Environment
- Financial Services
- Food and Beverage
- General Business
- Healthcare
- Hospitality
- Information Technology
- Insurance
- Heavy Industry & Manufacturing
- Media
- Mining
- People & Culture
- Pharmaceuticals
- Policy & Public Interest
- Real Estate
- Retail
- Sports
- Telecommunications
- Transportation
- Travel
- Utilities